BAFF, His-Avi-Tag Recombinant

Catalog #
100194
$445 *
Size: 50 µg
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant human BAFF (B-cell-activating factor, also known as TNFSF13B, Tumor necrosis factor ligand superfamily member 13B), encompassing amino acids 134-285. This construct contains an N-terminal His-tag (6xHis) followed by an Avi-Tag™. The recombinant protein was affinity purified.

Synonyms
TNFSF13B, Tumor necrosis factor ligand superfamily member 13B, DTL, BAFF, B lymphocyte stimulator, BLYS, CD257, TNF- and APOL-related leukocyte expressed ligand 1, TALL1, TALL-1, THANK, ZTNF4, TNLG7A, TNFSF20
Product Info
Storage and Usage
Citations
Species
Human
Construct
BAFF (His-Avi-134-285(end))
Host Species/Expression System
HEK293
Purity

≥90%

Format
Aqueous buffer solution
Formulation

8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol

MW
20 kDa + glycans
Amino Acids
134-285(end)
Glycosylation
This protein runs at a higher MW by SDS-PAGE due to glycosylation.
Genbank #
NM_006573
UniProt #
Q9Y275
Tag(s)
N-terminal His-Avi-Tag
Background

B-cell activating factor (BAFF) is a cytokine regulating B cell development, survival, and antibody production. It is a key player in the immune response and has implications in autoimmune diseases. It is a ligand for receptors TNFRSF13B/TACI, TNFRSF17/BCMA, and TNFRSF13C/BAFFR. BAFF normally maintains immune balance, and overproduction of BAFF leads to various auto-immune diseases. It is, therefore, a therapeutic target. Drugs that inhibit BAFF, such as belimumab, have been approved for the treatment of certain autoimmune disorders.

References

1. Knight AK, et al. Clin. Immunol. 124 (2), 182-189 (2007)

2. Hever, A., et al. Proc. Natl. Acad. Sci. U.S.A. 104 (30), 12451-12456 (2007)